Agreement Will Hasten Development of Alzheimer's Disease Diagnostic Test

The availability of an Alzheimer's disease (AD) test targeted to the protein p97 will enable earlier diagnosis, quantitative disease monitoring, and better patient outcomes. The p97 protein is a secreted protein specifically expressed by amyloid plaque-associated reactive microglia.

biOasis Technologies Inc. (South Surrey, BC, Canada) announced that a major step in the application of its p97 test for diagnosis of Alzheimer's disease was achieved by the signing of an agreement with UK-based Fleet Bioprocessing Ltd. (Fleet; Hartley Whitney, UK).

Rob Hutchison, CEO, biOasis commented, ''If earlier diagnosis and improved patient management result in delaying the average onset of the disease by even one-year, society would save in excess of U.S. $12 billion annually. The agreement with Fleet will reduce product development timelines for the biOasis p97 Alzheimer's test and enable faster entry into the $36 billion IVD market."

Fleet Bioprocessing are expert providers of high-quality contract development and manufacturing services. They meet the needs of the diagnostics, pharma, and biotech sectors, offering a range of services from purification and conjugation of proteins, through to immunoassay development and the formulation and dispensing of reagents.

biOasis Technologies Inc. is a company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing Ltd.